|
EP3153522A1
|
|
Process for the purification of erythropoietin and darbepoetin alfa
|
|
US2017101437A1
|
|
Process for purification of darbepoetin alfa
|
|
WO2009072137A2
|
|
Process for pure irbesartan
|
|
WO2009040825A1
|
|
A process for preparation of enantiomerically pure esomeprazole
|
|
EP2218713A1
|
|
Erlotinib hydrochloride polymorph Form A substantially free of polymorph Form B
|
|
US2010166850A1
|
|
Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
|
|
EP2295431A2
|
|
Substantially pure eprosartan free base
|
|
WO2009007984A2
|
|
An improved process for erlotinib hydrochloride
|
|
WO2009001367A2
|
|
Novel crystalline forms of atovaquone
|
|
EP2162449A2
|
|
Improved process for amorphous rabeprazole sodium
|
|
EP2097408A1
|
|
Improved process for eprosartan
|
|
WO2008068767A2
|
|
A novel crystalline form of lansoprazole
|
|
WO2008059512A1
|
|
Process for preparation of prulifloxacin using novel intermediates
|
|
EP2061783A2
|
|
Improved process for rimonabant
|
|
US2010076022A1
|
|
Novel polymorphs of rimonabant
|
|
EP2057151A2
|
|
Process for purification of aprepitant
|
|
WO2008015686A1
|
|
Stable multiparticulate formulations of didanosine
|
|
US2009275746A1
|
|
Solid faropenem free acid
|
|
US2007282129A1
|
|
Processes for preparing sertraline hydrochloride crystalline forms
|
|
WO2007083318A1
|
|
Process for isolation of desired isomers of nebivolol intermediates
|
